Crescita Therapeutics Inc. (CTX.TO)
CAD 0.57
(1.79%)
CAD 0.57
(1.79%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 17.52 Million CAD | -25.52% |
| 2022 | 23.52 Million CAD | 40.29% |
| 2021 | 16.76 Million CAD | 7.22% |
| 2020 | 15.64 Million CAD | -29.98% |
| 2019 | 22.33 Million CAD | 34.33% |
| 2018 | 16.62 Million CAD | 38.41% |
| 2017 | 12.01 Million CAD | 242.87% |
| 2016 | 3.5 Million CAD | 308.87% |
| 2015 | 857 Thousand CAD | 3.25% |
| 2014 | 830 Thousand CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 4.08 Million CAD | -18.17% |
| 2024 Q1 | 4.99 Million CAD | 5.74% |
| 2023 Q4 | 4.72 Million CAD | 55.79% |
| 2023 FY | 17.52 Million CAD | -25.52% |
| 2023 Q3 | 3.03 Million CAD | -41.24% |
| 2023 Q2 | 5.16 Million CAD | 12.17% |
| 2023 Q1 | 4.6 Million CAD | -23.68% |
| 2022 Q1 | 4.95 Million CAD | -34.53% |
| 2022 FY | 23.52 Million CAD | 40.29% |
| 2022 Q4 | 6.03 Million CAD | -0.03% |
| 2022 Q3 | 6.03 Million CAD | -7.37% |
| 2022 Q2 | 6.51 Million CAD | 31.53% |
| 2021 FY | 16.76 Million CAD | 7.22% |
| 2021 Q3 | 2.99 Million CAD | 1.49% |
| 2021 Q4 | 7.56 Million CAD | 152.66% |
| 2021 Q1 | 3.26 Million CAD | 16.98% |
| 2021 Q2 | 2.94 Million CAD | -9.68% |
| 2020 Q4 | 2.79 Million CAD | -61.77% |
| 2020 Q2 | 1.73 Million CAD | -54.57% |
| 2020 FY | 15.64 Million CAD | -29.98% |
| 2020 Q1 | 3.81 Million CAD | -0.13% |
| 2020 Q3 | 7.3 Million CAD | 321.29% |
| 2019 Q3 | 4.9 Million CAD | -47.6% |
| 2019 Q4 | 3.82 Million CAD | -22.14% |
| 2019 FY | 22.33 Million CAD | 34.33% |
| 2019 Q1 | 4.24 Million CAD | -31.51% |
| 2019 Q2 | 9.36 Million CAD | 120.33% |
| 2018 Q3 | 4.46 Million CAD | 93.16% |
| 2018 Q4 | 6.2 Million CAD | 38.98% |
| 2018 Q1 | 3.64 Million CAD | 54.88% |
| 2018 FY | 16.62 Million CAD | 38.41% |
| 2018 Q2 | 2.31 Million CAD | -36.67% |
| 2017 Q1 | 2.08 Million CAD | -7.47% |
| 2017 Q4 | 2.35 Million CAD | -13.38% |
| 2017 FY | 12.01 Million CAD | 242.87% |
| 2017 Q3 | 2.72 Million CAD | -44.01% |
| 2017 Q2 | 4.85 Million CAD | 133.56% |
| 2016 Q2 | 154 Thousand CAD | -33.33% |
| 2016 FY | 3.5 Million CAD | 308.87% |
| 2016 Q4 | 2.24 Million CAD | 111.48% |
| 2016 Q1 | 231 Thousand CAD | -66.47% |
| 2016 Q3 | 1.06 Million CAD | 590.26% |
| 2015 Q4 | 689 Thousand CAD | 2275.86% |
| 2015 Q2 | 287 Thousand CAD | 34.11% |
| 2015 Q3 | 29 Thousand CAD | -89.9% |
| 2015 FY | 857 Thousand CAD | 3.25% |
| 2015 Q1 | 214 Thousand CAD | 0.0% |
| 2014 FY | 830 Thousand CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aurora Cannabis Inc. | 270.28 Million CAD | 93.517% |
| Avicanna Inc. | 16.79 Million CAD | -4.351% |
| Avant Brands Inc. | 26.34 Million CAD | 33.488% |
| Cardiol Therapeutics Inc. | - CAD | -Infinity% |
| Knight Therapeutics Inc. | 328.19 Million CAD | 94.661% |
| MediPharm Labs Corp. | 33.06 Million CAD | 47.003% |
| OrganiGram Holdings Inc. | 149.2 Million CAD | 88.256% |
| Canopy Growth Corporation | 297.14 Million CAD | 94.103% |
| Willow Biosciences Inc. | 1.17 Million CAD | -1395.051% |
| Auxly Cannabis Group Inc. | 101.07 Million CAD | 82.665% |